MDNAF — Medicenna Therapeutics Share Price
0.000.00%
Last trade - 00:00- $50.74m
- $28.87m
- 14
- 11
- 42
- 10
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.97 | ||
| Price to Tang. Book | 3.98 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -64.3% | ||
| Return on Equity | -149.09% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
Directors
- Fahar Merchant CHM
- Elizabeth Williams CFO
- Rosemina Merchant OTH
- Martin Bexon OTH
- Chandrakant Panchal LED
- Albert Beraldo IND
- Karen Dawes IND (69)
- Jack Geltosky IND
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 2nd, 2015
- Public Since
- July 13th, 2015
- No. of Employees
- 16
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 83,380,737
- Address
- 2 Bloor St W., 7Th Floor, TORONTO, M4W 3E2
- Web
- https://www.medicenna.com
- Phone
- +1 4166485555
- Auditors
- MNP LLP
Upcoming Events for MDNAF
Medicenna Therapeutics Corp Annual Shareholders Meeting
Q2 2026 Medicenna Therapeutics Corp Earnings Release
Similar to MDNAF
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Medicenna Therapeutics share price?
As of Today at 21:58 UTC, shares in Medicenna Therapeutics are trading at $0.61. This share price information is delayed by 15 minutes.
How has the Medicenna Therapeutics share price performed this year?
Shares in Medicenna Therapeutics last closed at $0.61 and the price had moved by -58.22% over the past 365 days. In terms of relative price strength the Medicenna Therapeutics share price has underperformed the S&P500 Index by -63.11% over the past year.
What are the analyst and broker recommendations for Medicenna Therapeutics?
The overall consensus recommendation for Medicenna Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Medicenna Therapeutics dividend yield?
Medicenna Therapeutics does not currently pay a dividend.
Does Medicenna Therapeutics pay a dividend?
Medicenna Therapeutics does not currently pay a dividend.
When does Medicenna Therapeutics next pay dividends?
Medicenna Therapeutics does not currently pay a dividend.
How do I buy Medicenna Therapeutics shares?
To buy shares in Medicenna Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Medicenna Therapeutics?
As of the previous close price of $0.61, shares in Medicenna Therapeutics had a market capitalisation of $50.74m.
Where are Medicenna Therapeutics shares listed?
Here are the trading details for Medicenna Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: MDNAF
What kind of share is Medicenna Therapeutics?
Based on an overall assessment of its quality, value and momentum Medicenna Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Medicenna Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Medicenna Therapeutics is $2.51. That is 312.24% above the last closing price of $0.61.
Analysts covering Medicenna Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.25 for the next financial year.
Find out moreWhat is the trend in the Medicenna Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medicenna Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -53.35%.
As of the last closing price of $0.61, shares in Medicenna Therapeutics were trading -40.94% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Medicenna Therapeutics PE Ratio?
The Medicenna Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Medicenna Therapeutics?
Medicenna Therapeutics' management team is headed by:
- Fahar Merchant - CHM
- Elizabeth Williams - CFO
- Rosemina Merchant - OTH
- Martin Bexon - OTH
- Chandrakant Panchal - LED
- Albert Beraldo - IND
- Karen Dawes - IND
- Jack Geltosky - IND